Stratifies chronic lymphocytic leukemia patients into four risk categories based on five independent prognostic factors. The CLL-IPI combines genetic (TP53 status, IGHV mutational status), biochemical (β2-microglobulin), and clinical parameters (age, clinical stage) to predict overall survival and treatment outcomes. This validated prognostic model discriminates four risk groups with significantly different 5-year overall survival rates: low risk (93.2%), intermediate risk (79.3%), high risk (63.3%), and very high risk (23.3%). The CLL-IPI enables more targeted patient management and risk-adapted treatment strategies in clinical practice and clinical trials.
Awaiting Clinical Input
Enter the clinical input parameters on the left and click Run Clinical Assessment to evaluate this medical calculator with deterministic clinical scoring.
The International Prognostic Index for Chronic Lymphocytic Leukemia (CLL-IPI) is utilized in clinical practice for risk stratification, diagnostic probability estimation, and treatment decision-making within hematology.
Use this tool during initial patient intake, emergency department workup, or bedside assessment when objective clinical scoring is required to guide management or admission decisions.
Score 0-1 points
Score 2-3 points
Score 4-6 points
Score 7-10 points
Run this calculator with patient history, laboratory integration, and drug interaction safety checks on the DexaMed clinician app.
Open in Web AppClinical Decision Support (CDS) Notice & Legal Disclaimer
This medical calculator and its scoring interpretation are provided strictly for licensed healthcare professionals and medical trainees as an educational and clinical decision support instrument. It does not replace independent clinical judgment, comprehensive patient history, physical examination, or attending physician oversight. Not FDA-cleared as an autonomous diagnostic medical device. Read the full DexaMed Medical Disclaimer.